Avidity Biosciences Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 428

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.8B

Avidity Biosciences General Information

Description

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Contact Information

Formerly Known As
Avidity NanoMedicines
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 3020 Callan Road
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 3020 Callan Road
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avidity Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 27-Feb-2026 $10.8B Completed Generating Revenue
11. 2PO 10-Sep-2025 Completed Generating Revenue
10. 2PO 15-Aug-2024 Completed Generating Revenue
9. 2PO 12-Jun-2024 Completed Generating Revenue
8. PIPE 04-Mar-2024 Completed Generating Revenue
7. IPO 12-Jun-2020 Completed Generating Revenue
6. Later Stage VC (Series C) 13-Nov-2019 Completed Generating Revenue
5. Later Stage VC 22-Apr-2019 Completed Generating Revenue
4. Corporate 17-Oct-2018 $25M Completed Generating Revenue
3. Later Stage VC (Series B) 05-Jan-2017 $16M $25M Completed Startup
To view Avidity Biosciences’s complete valuation and funding history, request access »

Avidity Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called An
Drug Discovery
San Diego, CA
428 As of 2026

Waltham, MA
 

Mainz, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Avidity Biosciences Competitors (38)

One of Avidity Biosciences’s 38 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dyne Therapeutics Formerly VC-backed Waltham, MA
BioNTech Formerly VC-backed Mainz, Germany
Arcturus Therapeutics Holdings Formerly VC-backed San Diego, CA
Protagonist Therapeutics Formerly VC-backed Newark, CA
Bicycle Therapeutics Formerly VC-backed Cambridge, United Kingdom
You’re viewing 5 of 38 competitors. Get the full list »

Avidity Biosciences Patents

Avidity Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260258160-A1 Novel preparation of oligonucleotide conjugates using transition metals or salts thereof Pending 19-Dec-2024
US-20260191980-A1 Methods of treating cardiomyopathy using prkag2-targeting antibody-oligonucleotide conjugates Pending 08-Nov-2024
US-20260153519-A1 Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy Pending 30-Oct-2024
WO-2026096668-A2 Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy Pending 30-Oct-2024
WO-2026096668-A3 Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy Pending 30-Oct-2024 G01N33/6887
To view Avidity Biosciences’s complete patent history, request access »

Avidity Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avidity Biosciences Former Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
Alethea Capital Management Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Avoro Capital Venture Capital Minority
Boxer Capital Corporate Venture Capital Minority
You’re viewing 5 of 28 investors. Get the full list »

Avidity Biosciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.97 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Avidity Biosciences’s complete esg history, request access »

Avidity Biosciences FAQs

  • When was Avidity Biosciences founded?

    Avidity Biosciences was founded in 2012.

  • Where is Avidity Biosciences headquartered?

    Avidity Biosciences is headquartered in San Diego, CA.

  • What is the size of Avidity Biosciences?

    Avidity Biosciences has 428 total employees.

  • What industry is Avidity Biosciences in?

    Avidity Biosciences’s primary industry is Drug Discovery.

  • Is Avidity Biosciences a private or public company?

    Avidity Biosciences is a Private company.

  • What is the current valuation of Avidity Biosciences?

    The current valuation of Avidity Biosciences is .

  • What is Avidity Biosciences’s current revenue?

    The current revenue for Avidity Biosciences is .

  • How much funding has Avidity Biosciences raised over time?

    Avidity Biosciences has raised $2.15B.

  • Who are Avidity Biosciences’s investors?

    Adage Capital Management, Alethea Capital Management, Alexandria Venture Investments, Avoro Capital, and Boxer Capital are 5 of 28 investors who have invested in Avidity Biosciences.

  • Who are Avidity Biosciences’s competitors?

    Dyne Therapeutics, BioNTech, Arcturus Therapeutics Holdings, Protagonist Therapeutics, and Bicycle Therapeutics are some of the 38 competitors of Avidity Biosciences.

  • When was Avidity Biosciences acquired?

    Avidity Biosciences was acquired on 27-Feb-2026.

  • Who acquired Avidity Biosciences?

    Avidity Biosciences was acquired by Novartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process